Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
NCT07288515 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-04-17
Summary
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-31
- Primary Completion
- 2029-12-31
- Completion
- 2029-12-31
Countries
- Belarus
Study Locations
More Related Trials
-
Early Intervention With Acalabrutinib in Patients With High Risk CLL
NCT04660045 ·Status: WITHDRAWN ·Phase: PHASE2
-
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
National Acalabrutinib Observational Study
NCT05437250 ·Status: ACTIVE_NOT_RECRUITING
-
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
NCT04008706 ·Status: COMPLETED ·Phase: PHASE3
-
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
NCT02157324 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
NCT05971251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CLL Therapy Approaches in Russia
NCT05140369 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06757647 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
NCT06548152 ·Status: RECRUITING
-
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337829 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
NCT04722172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
NCT02328014 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
NCT04883749 ·Status: COMPLETED ·Phase: PHASE2
-
MEOI and HRQoL in CLL Patients Treated With BTKis
NCT04938141 ·Status: COMPLETED
-
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942 ·Status: COMPLETED ·Phase: PHASE3
-
Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness
NCT03881592 ·Status: UNKNOWN
-
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Study of Acalabrutinib
NCT06767891 ·Status: ENROLLING_BY_INVITATION
-
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia
NCT04178798 ·Status: COMPLETED ·Phase: PHASE3
-
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
NCT05975164 ·Status: UNKNOWN
-
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192 ·Status: RECRUITING ·Phase: PHASE3